Mednax (MD) Tops Q2 EPS by 3c; Guides Q3 EPS; Comps Growth of 1.5% in Q212

Mednax (NYSE: MD) reported Q2 EPS of $1.22, $0.03 better than the analyst estimate of $1.19. Revenue for the quarter came in at $449.5 million versus the consensus estimate of $437.33 million.

Same-unit growth attributable to patient volume grew by 1.5 percent.

Mednax sees Q3 2012 EPS of $1.25-$1.30, versus the consensus of $1.26.

For earnings history and earnings-related data on Mednax (MD) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Optimum Communications gets NYSE non-compliance notice over stock price